The 56 references in paper M. Novikova C., E. Levankovskaya I., M. Shvetsov Yu., A. Zilov V., E. Shilov M., М. Новикова С., Е. Леванковская И., М. Швецов Ю., А. Зилов В., Е. Шилов М. (2013) “ВОЗМОЖНОСТИ ТЕРАПИИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК: КОРРЕКЦИЯ ИНСУЛИНОРЕЗИСТЕНТНОСТИ (ОБЗОР ЛИТЕРАТУРЫ И СОБСТВЕННЫЕ ДАННЫЕ) // POSSIBILITIES OF THERAPY OF THE CHRONIC KIDNEY DISEASE: CORRECTION INSULIN RESISTANCE (REVIEW OF LITERATURE AND OWN DATA)” / spz:neicon:nefr:y:2013:i:4:p:17-25

1
Гурьева ИВ. Общее руководство Международной Диабетической Федерации по сахарному диабету 2 типа (краткое изложение). Сах диабет 2007; 4: 54
(check this in PDF content)
2
Menon V, Li L, Wang X et al. Relationship between Creactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis 2003; 42 (1): 44-52
(check this in PDF content)
3
Muntner P, He J, Astor BC et al. Traditional and Nontraditional Risk Factors Predict Coronary Heart Disease in Chronic Рис. 6. Изменение (Δ) показателей почечного процесса и ИР (индекс НОМА) через 6 мес лечения в группах стандартной терапии, сулодексида и комбинации препаратов (метформин и сулодексид) в сочетании со стандартной терапией. Kidney Disease: Results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 2005; 16: 529-538
(check this in PDF content)
4
Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140: 167–174
(check this in PDF content)
5
Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005; 16: 2134–2140
(check this in PDF content)
6
Мухин НА, Моисеев ВС, Кобалава ЖД и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер арх 2004; 6: 39-47
(check this in PDF content)
7
Mann JFE. Cardiovaskular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors. Kidney Int 2003; 63: 192-196
(check this in PDF content)
8
Parikh NI, Hwang SJ, Larson MG et al. Chronic kidney disease as a Predictor of the cardiovascular disease (from the Framingham Heart Study). Am J Cardiol 2008; 102: 47-53
(check this in PDF content)
9
Дедов ИИ, Мельниченко ГА (ред.). Ожирение. Мед. информ. агентство. М.: 2004; 48-99
(check this in PDF content)
10
Дедов ИИ, Балаболкин МИ, Мамаева ГГ и др. Инсулиновая резистентность и роль гормонов жировой ткани в развитии сахарного диабета. Пособие для врачей. М., 2005
(check this in PDF content)
11
Anastassios JP, Nandini AJ, Greenberg AS. Adipocytokines and Insulin Resistance. J Clin Endocrinol Metab 2004; 89(2): 447-452
(check this in PDF content)
12
Новикова МС, Калинченко СЮ, Борисов ВВ. Метаболический синдром и хроническая болезнь почек: роль возрастного андрогенного дефицита. Новые подходы к лечению. Тер арх 2008; 80(10): 41-46
(check this in PDF content)
13
Palatini P, Mormino P, Dorigatti F. Glomerular hyperfiltration predicts the development of microalbuminuria in stage 1 hypertention: The HARVEST. Kidney Int 2006; 70: 578-584
(check this in PDF content)
14
Chagnac A, Weinstain T, Korzets A et al. Glomerular hemodynamics in severe obesity. Am Physiol Renal Physiol 2000; 278 (5): 817-22
(check this in PDF content)
15
Shastri Sh, Sarnak MJ. High eGFR and mortality: high true GFR or a marker of frailty? Nat Rev Nephrol 2011; 7: 680–682
(check this in PDF content)
16
Stellato RK, Feldman HA, Hamdy O. Testosterone, sex hormone binding globulin and testosterone predict the development of non insulin dependent diabetes mellitus in men. Am J Epidemiol 1996; 143: 889-97
(check this in PDF content)
17
Khaw K, Chir M, Dowsett M et al. Endogenous Testosterone and Mortality Due to All Causes,Cardiovascular Disease, and Cancer in Men European Prospective Investigation Into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007; 116: 2694-2701
(check this in PDF content)
18
Kaartinen K, Syrjanen J, Harmoinen A et al. Insulin resistance and the progression of IgA glomerulonephritis. Nephrol Dial Transplant 2007; 22: 778-788
(check this in PDF content)
19
Porrini E, Bayes B, Diaz JM et al. Hyperinsulinemia and Hyperfiltration in Renal Transplantation. Transplant 2009; 87: 274-279
(check this in PDF content)
20
Кутырина ИМ, Шестакова МВ, Савельева СА и др. Вклад ожирения в поражение почек у больных с сахарным диабетом 2 типа. Тер арх 2010; 6: 21-25
(check this in PDF content)
21
Wahba IM, Mak RH. Obesity and obesity-mediated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 550-562
(check this in PDF content)
22
Тугушева ФА, Зубина ИМ, Митрофанова ОВ. Окисидативный стресс и хроническая болезнь почек. Нефрология 2007; 11(3): 29-47
(check this in PDF content)
23
Guichard C, Moreau R, Pessayre D et al. NOX family NADPH oxidases in liver and pancreatic islets: A role in the metabolic syndrome and diabetes? Biochem Soc Trans 2008; 36: 920-929
(check this in PDF content)
24
Фонсека В (ред.). Метаболический синдром. Практика, М., 2011; 192-203
(check this in PDF content)
25
Мухин НА, Фомин ВВ, Сагинова ЕА. Эндотелиальная дисфункция и поражение почек при ожирении. Вестн РАМН 2006; 12: 25-31
(check this in PDF content)
26
Сагинова ЕА, Галлямов МГ, Северова ММ. Современные представления о поражении почек при ожирении. Клин нефрол 2010; 2: 66-71
(check this in PDF content)
27
Нанчикеева МЛ, Козловская ЛВ, Фомин ВВ и др. Клиническое значение определения в моче маркеров эндотелиальной дисфункции и фиброгенеза у больных артериальной гипертензией с поражением почек. Клин нефрол 2009; 4: 54-58
(check this in PDF content)
28
Кутырина ИМ, Крячкова АА, Савельева СА, Шестакова МВ. Роль альдостерона в поражении почек при метаболическом синдроме, ассоциированном с ожирением. Клин нефрол 2010; 4: 34-38
(check this in PDF content)
29
Fowler J, Krueth S, Bernlohr D, Katz S. Renin dynamics in adipose tissue: adipose tissue control of local renin concentrations. Am J Physiol Endocrinol Metab 2009; 296 (2): 343–350
(check this in PDF content)
30
Kamijo A, Kimura K, Sugaya T et al. Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int 2002; 62: 1628-1637
(check this in PDF content)
31
Thomas ME, Harris KP, Walls J et al. Fatty acids exacerbate tubulointerstitial injury in protein-overload proteinuria. Am J Physiol Renal Physiol 2002; 283: F640-F647
(check this in PDF content)
32
Wu Y, Liu Z, Xiang Z et al. Obesity-related glomerulopathy: Insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology 2006; 147: 44-50
(check this in PDF content)
33
Jiang T, Liebman SE, Lusia MS et al. Role of altered renal lipid metabolism and the sterol regulatory element binding proteins in the pathogenesis of age-related renal disease. Kidney Int 2005; 68: 2608-2620
(check this in PDF content)
34
Федорова ЕЮ, Кутырина ИМ. Механизмы прогрессирования поражения почек при ожирении. Нефрология и диализ 2006;8(2):102-111
(check this in PDF content)
35
Ruan X, Guan Y. Metabolic syndrome and chronic kidney disease. J Diabetes 2009; 1: 236-245
(check this in PDF content)
36
Fliser D, Pacini G, Engelleiter R et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998;53:1343-1347
(check this in PDF content)
37
Sechi A, Catena C, Zingaro L et al. Abnormalities of glucose metabolism in patients with early renal failure. Diabetes 2002;15:1226-1232
(check this in PDF content)
38
Wahba IM, Mak RH. Obesity and obesity-mediated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2007;2:550-562
(check this in PDF content)
39
Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Program Research Group. N Engl J Med 2002; 346: 393-403
(check this in PDF content)
40
Ramachandran A, Snehalatha C, Mary S et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance. Diabetologia 2006; 49: 289-297
(check this in PDF content)
41
Fontbonne A, Charles M, Juhan-Vague I et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 1996; 19: 920-926
(check this in PDF content)
42
Cabalero AE, Delgado A, Aguilar-Salinas CA et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trail. J Clin Endocrinol Metab 2004;89(8):3943-3948
(check this in PDF content)
43
Aguiar LGR, Bahia LR, Villela N et. al. Metformin improves enodethelial vascular reactivity in first-degree relatives of type diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care 2006; 29: 1083-1089
(check this in PDF content)
44
Isoda K, Young JL, Zirlik A et al. Human Vascular Wall Cells Metformin Inhibits Proinflammatory Responses and Nuclear Factor-kB in Human Vascular Wall Cells. Arterioscler Thromb Vasc Biol 2006; 26: 611-617
(check this in PDF content)
45
Fronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The multicenter metformin group. N Engl J Med 1995; 333: 541-549
(check this in PDF content)
46
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865
(check this in PDF content)
47
Holmes D, Fitzeqerald P, Goldberg AM et al. The PRESTO (Prevention of restenosis with tranilast and its outcomes) protocol: a double-blind, placebo-controlled trial. Am Heart J 2000; 139: 23-31
(check this in PDF content)
48
Colagium S, Flack J, Barker G et al. National Evidence Based Guideline for Blood Glucose control in type 2 diabetes 2009; 121-128
(check this in PDF content)
49
Dedov I, Shestakova M, Vorontzov A, Palazzini E. A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrol Dial Transplant 1997; 12: 2295–2300
(check this in PDF content)
50
Семенова ИВ, Чугунова ЛА, Ильин АВ и др. Влияние гликозаминогликанов на течение диабетической нефропатии на стадии микроальбуминурии у больных сахарным диабетом 2 типа. Сахарный диабет 2010; 2: 2-7
(check this in PDF content)
51
Blouza S, Dakhli S, Abid H et al. Efficacy of low-dose oral sulodexidein the management of diabetic nephropathy. J Nephrol 2010; 23 (04): 415-424
(check this in PDF content)
52
Gambaro G, Kinalska I, Oksa A, Pont’uch P. Oral Sulodexide Reduces Albuminuria in Microalbuminuric and Macroalbuminuric Type 1 and Type 2 Diabetic Patients: The Di.N.A.S. Randomized Trial. J Am Soc Nephrol 2002; 13: 1615–1625
(check this in PDF content)
53
Gluhovschi G, Schiller A, Raica M et al. The effects of the therapy with natural glycosaminoglycans (sulodexide) on proteinuria in different types of glomerulonephritis. Medicine and Biology 2001; 8(1): 26-30
(check this in PDF content)
54
Bang K, Chin HJ, Chae DW et al. Anti-Proteinuric Effect of Sulodexide in Immunoglobulin A Nephropathy. Yonsei Med J 2011; 52: 588-594
(check this in PDF content)
55
Broekhuizen LN, Lemkes BA, Mooij HL et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010;52(12):2646-2655
(check this in PDF content)
56
Gambaro G, Kong NCT. Glycosaminoglycan treatment in glomerulonephritis? An interesting option to investigate. J Nephrol 2010; 23 (03): 244-252 Поступила в редакцию 29.05.2013 г. Принята в печать 02.07.2013 г.
(check this in PDF content)